Tags

Type your tag names separated by a space and hit enter

The impact of omega-3 fatty acid supplementation on glycemic control in patients with gestational diabetes: a systematic review and meta-analysis of randomized controlled studies.
J Matern Fetal Neonatal Med. 2020 May; 33(10):1767-1773.JM

Abstract

Background:

Omega-3 fatty acid supplementation shows some treatment efficacy for gestational diabetes. This systematic review and meta-analysis is conducted to investigate the efficacy of omega-3 fatty acid supplementation for glycemic control in patients with gestational diabetes.

Methods:

The databases including PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases are systematically searched for collecting the randomized controlled trials (RCTs) regarding the efficacy of omega-3 fatty acid versus placebo for gestational diabetes.

Results:

This meta-analysis has included seven RCTs. Compared with placebo group in patients with gestational diabetes, omega-3 fatty acids supplementation results in remarkably reduced fasting plasma glucose (FPG) (standard mean difference (std. MD) = -0.56; 95% confidence interval (CI) = -0.87 to -0.24; p = .0005), homeostatic model of assessment for insulin resistance (HOMA-IR) (std. MD = -0.52; 95% CI = -0.83 to -0.21; p = .001), but has no statistical impact on macrosomia (risk ratio (RR) = 0.48; 95% CI = 0.22-1.02; p = .06), newborns' hyperbilirubinemia (RR = 0.46; 95% CI = 0.19-1.10; p = .08), nitric oxide (NO) (std. MD = 0.17; 95% CI = -0.64-0.98; p = .68), preterm delivery (RR = 1.75; 95% CI = 0.08-3.80; p=.16) and preeclampsia (RR =0.74; 95% CI = 0.26-2.16; p = .59). However, notably decreased high sensitivity C-reactive protein (hs-CRP) is revealed after omega-3 fatty acids supplementation (std. MD = -1.14; 95% CI = -2.0 to -0.29; p = .009).

Conclusions:

Omega-3 fatty acids supplementation can provide substantially beneficial effects on glycemic control and inflammatory response for gestational diabetes.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China.Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China.Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China.Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China.Department of Obstetrics and Gynecology, Chongqing Health Center for Women and Children, Chongqing, China.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

30231792

Citation

Gao, Li, et al. "The Impact of Omega-3 Fatty Acid Supplementation On Glycemic Control in Patients With Gestational Diabetes: a Systematic Review and Meta-analysis of Randomized Controlled Studies." The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, vol. 33, no. 10, 2020, pp. 1767-1773.
Gao L, Lin L, Shan N, et al. The impact of omega-3 fatty acid supplementation on glycemic control in patients with gestational diabetes: a systematic review and meta-analysis of randomized controlled studies. J Matern Fetal Neonatal Med. 2020;33(10):1767-1773.
Gao, L., Lin, L., Shan, N., Ren, C. Y., Long, X., Sun, Y. H., & Wang, L. (2020). The impact of omega-3 fatty acid supplementation on glycemic control in patients with gestational diabetes: a systematic review and meta-analysis of randomized controlled studies. The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 33(10), 1767-1773. https://doi.org/10.1080/14767058.2018.1526916
Gao L, et al. The Impact of Omega-3 Fatty Acid Supplementation On Glycemic Control in Patients With Gestational Diabetes: a Systematic Review and Meta-analysis of Randomized Controlled Studies. J Matern Fetal Neonatal Med. 2020;33(10):1767-1773. PubMed PMID: 30231792.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The impact of omega-3 fatty acid supplementation on glycemic control in patients with gestational diabetes: a systematic review and meta-analysis of randomized controlled studies. AU - Gao,Li, AU - Lin,Liyuan, AU - Shan,Nan, AU - Ren,Chun-Yan, AU - Long,Xin, AU - Sun,Yu-Han, AU - Wang,Lan, Y1 - 2018/10/29/ PY - 2018/9/21/pubmed PY - 2021/1/27/medline PY - 2018/9/21/entrez KW - Gestational diabetes KW - glycemic control KW - meta-analysis KW - omega-3 fatty acid KW - randomized controlled trials SP - 1767 EP - 1773 JF - The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians JO - J Matern Fetal Neonatal Med VL - 33 IS - 10 N2 - Background: Omega-3 fatty acid supplementation shows some treatment efficacy for gestational diabetes. This systematic review and meta-analysis is conducted to investigate the efficacy of omega-3 fatty acid supplementation for glycemic control in patients with gestational diabetes.Methods: The databases including PubMed, Embase, Web of science, EBSCO, and Cochrane Library databases are systematically searched for collecting the randomized controlled trials (RCTs) regarding the efficacy of omega-3 fatty acid versus placebo for gestational diabetes.Results: This meta-analysis has included seven RCTs. Compared with placebo group in patients with gestational diabetes, omega-3 fatty acids supplementation results in remarkably reduced fasting plasma glucose (FPG) (standard mean difference (std. MD) = -0.56; 95% confidence interval (CI) = -0.87 to -0.24; p = .0005), homeostatic model of assessment for insulin resistance (HOMA-IR) (std. MD = -0.52; 95% CI = -0.83 to -0.21; p = .001), but has no statistical impact on macrosomia (risk ratio (RR) = 0.48; 95% CI = 0.22-1.02; p = .06), newborns' hyperbilirubinemia (RR = 0.46; 95% CI = 0.19-1.10; p = .08), nitric oxide (NO) (std. MD = 0.17; 95% CI = -0.64-0.98; p = .68), preterm delivery (RR = 1.75; 95% CI = 0.08-3.80; p=.16) and preeclampsia (RR =0.74; 95% CI = 0.26-2.16; p = .59). However, notably decreased high sensitivity C-reactive protein (hs-CRP) is revealed after omega-3 fatty acids supplementation (std. MD = -1.14; 95% CI = -2.0 to -0.29; p = .009).Conclusions: Omega-3 fatty acids supplementation can provide substantially beneficial effects on glycemic control and inflammatory response for gestational diabetes. SN - 1476-4954 UR - https://www.unboundmedicine.com/medline/citation/30231792/The_impact_of_omega_3_fatty_acid_supplementation_on_glycemic_control_in_patients_with_gestational_diabetes:_a_systematic_review_and_meta_analysis_of_randomized_controlled_studies_ L2 - https://www.tandfonline.com/doi/full/10.1080/14767058.2018.1526916 DB - PRIME DP - Unbound Medicine ER -